NCT03295916 (STOMP) is a EARLY_PHASE1 clinical trial of Stereotactic Body Radiotherapy in Breast Cancer, sponsored by Juravinski Cancer Center.

Who is sponsoring NCT03295916?

NCT03295916 is sponsored by Juravinski Cancer Center.

What drugs are being tested in NCT03295916?

Interventions in NCT03295916: Stereotactic Body Radiotherapy.

What condition does NCT03295916 study?

NCT03295916 studies Breast Cancer.

Is NCT03295916 still recruiting?

NCT03295916 is currently status unknown. Last updated 29 January 2020.

Last reviewed 2020-01-29 · How we verify

NCT03295916: STOMP

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis

Status unknown EARLY_PHASE1 Last updated 29 January 2020

What this trial tests

EARLY_PHASE1 trial testing Stereotactic Body Radiotherapy in Breast Cancer in 30 participants. Status unknown.

Timeline

1 January 2018

Primary endpoint
1 April 2020

1 April 2021

Quick facts

Lead sponsor	Juravinski Cancer Center
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 January 2018
Primary completion	1 April 2020
Estimated completion	1 April 2021
Sites	1 location across Canada

Drugs / interventions tested

Stereotactic Body Radiotherapy

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

Juravinski Cancer Center

Who can join

18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate feasibility to treat metachronous multi-site breast cancer oligometastasis with stereotactic body radiotherapy (SBRT) in patients on systemic therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Stereotactic Body Radiotherapy

Trials testing the same drug.

NCT06391242 — Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases · Phase 3 · recruiting
NCT06201078 — Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy · Phase 2 · recruiting
NCT05678010 — A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer · Phase 1 · active not recruiting
NCT05433701 — Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC · NA · active not recruiting
NCT06546267 — Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART) · recruiting

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Juravinski Cancer Center trials

Trials by the same sponsor.

NCT06489821 — STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer · NA · not yet recruiting
NCT03380806 — Prostate Boost Irradiation With Stereotactic Body RT (SBRT) · Phase 2 · unknown
NCT03529708 — Stereotactic Body Radiotherapy Boost After Palliative Radiotherapy for Spinal Cord Compression · NA · unknown
NCT03196778 — Low Dose Hemi-body Radiation For Recurrent Prostate Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03295916 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juravinski Cancer Center
Last refreshed: 29 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03295916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing